Progress curve analysis of CYP1A2 inhibition: A more informative approach to the assessment of mechanism-based inactivation?

Drug Metabolism and Disposition

Volumn 35, Issue 12, 2007, Pages 2159-2165

  Fairman, D A ^a   Collins, C ^a   Chapple, S ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b UNIVERSITY OF PLYMOUTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; DIHYDRALAZINE; FURAFYLLINE; OLTIPRAZ; PAROXETINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RESVERATROL;

ARTICLE; DIALYSIS; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; LIVER MICROSOME; PRIORITY JOURNAL;

CYTOCHROME P-450 CYP1A2; DIHYDRALAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; KINETICS; MICROSOMES, LIVER; MODELS, BIOLOGICAL; NADP; PAROXETINE; PYRAZINES; STILBENES; THEOPHYLLINE;

EID: 36349009310     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.017236     Document Type: Article

References (24)

1. Brown HS, Ito K, Galetin A, and Houston JB (2005) Prediction of in vivo drug-drug interactions from in-vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 60:508-518.
2. Chang TKH, Chen J, and Lee WBK (2001) Differential inhibition & inactivation of Human CYP1 enzymes by trans resveratrol: evidence for mechanism-based inhibition of CYP1A2. J Pharmacol Exp Ther 299:874-882.
3. Dash C, Phadtare S, Deshpande V, and Rao M (2001) Structural and mechanistic insight into the inhibition of aspartic proteases by a slow-tight binding inhibitor from an extremophilic Bacillus sp.: correlation of the kinetic parameters with the inhibitor induced conformational changes. Biochemistry 40:11525-11532.
4. Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT, and Rostami-Hodjegan A (2006) A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro to in vivo extrapolation. Curr Drug Metab 7:315-334.
5. Ito K, Halifax D, Obach RS, and Houston JB (2005) Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 33:837-844.
6. Kitz R and Wilson IB (1962) Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 237:3245-3249.
7. Kunze KL and Trager WF (1993) Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 6:646-656.
8. Langouet S, Furge L, Kerriguy N, Nakamura K, Guillouzo A, and Guengerich FP (2000) Inhibition of human cytochrome P450 enzymes by 1,2-dithiole-3-thione, oltipraz and its derivatives, and sulphaphane. Chem Res Toxicol 13:245-252.
9. Lin JH and Lu AYH (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361-390.
10. Masubuchi Y and Horie T (1999) Mechanism-based inactivation of cytochrome P450s 1A2 & 3A4 by dihydralazine in human liver microsomes. Chem Res Toxicol 12:1028-1032.
11. Maurer ST, Tabrizi-Fard, and Fung HL (2000) Impact of mechanism-based inactivation on inhibitor potency: implications for rational drug discovery. J Pharm Sci 89:1404-1412.
12. Morrison JF and Walsh CT (1988) The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 61:201-301.
13. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston BJ, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
14. Obach RS, Walsky RL, and Venkatakrishnan K (2007) Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246-255.
15. Orson BA and Tipton KF (1979) Kinetic analysis of progress curves. Methods Enzymol 63:159-183.
16. Pope AJ, Moore KJ, McVey M, Mensah L, Benson N, Osbourne N, Broom N, Brown MJB, and O'Hanlon P (1998) Characterization of isoleucyl-tRNA synthetase from Staphylococcus aureus. J Biol Chem 273:31691-31701.
17. Silverman RB (1995) Mechanism-based enzyme inactivators. Methods Enzymol 249:240-283.
18. Spaldin V, Madden S, Adams DA, Edwards RJ, Davies DS, and Park BK (1995) Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe. Drug Metab Dispos 23:929-934.
19. Tarrus E, Cami J, Roberts DJ, Spickett RGW, Celdran E, and Segura J (1987) Accumulation of caffeine in healthy volunteers treated with furafylline. Br J Clin Pharmacol 49:49-58.
20. Thomas KH, Chang JC, and Lee WBK (2001) Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther 299:874-882.
21. Von Moltke LL, Greenblatt DJ, Duan SX, Schmider J (1996) Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. Psychopharmacology 128:398-407.
22. Walsh C, Cromartie T, Marcotte P, and Spencer R (1978) Suicide substrates for flavoprotein enzymes. Methods Enzymol 53:437-448.
23. Yang J, Jamei M, Rowland-Yeo K, Tucker GT, and Rostami-Hodjegan A (2005) Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol. Eur J Pharm Sci 26:334-340.
24. Zhao P, Kunze KL, and Lee CA (2004) Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metab Dispos 33:853-861.